Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study Full Text
Cardiovascular Diabetology, 07/23/2012
Al–Daghri NM et al. – In the Saudi diabetes mellitus type 2 (T2DM) population receiving oral Vitamin D3 supplementation (2000 IU/day), circulating 25–hydroxyvitamin D levels remained below normal 18 months after the onset of treatment. Yet, this "suboptimal" supplementation significantly improved lipid profile with a favorable change in HDL/LDL ratio, and HOMA–beta function, which were more pronounced in T2DM females.
Methods- T2DM Saudi subjects (men, N=34: Age: 56.6 +/– 8.7 yr, BMI, 29.1 +/– 3.3kg/m2; women, N=58: Age: 51.2 +/– 10.6 yr, BMI 34.3 +/– 4.9 kg/m2;) were recruited and given 2000 IU vitamin D3 daily for 18 months.
- Anthropometrics and fasting blood were collected (0, 6, 12, 18 months) to monitor serum 25–hydroxyvitamin D using specific ELISA, and to determine metabolic profiles by standard methods.
- In all subjects there was a significant increase in mean 25–hydroxyvitamin D levels from baseline (32.2+/–1.5nmol/L) to 18 months (54.7+/–1.5nmol/L; p<0.001), as well as serum calcium (baseline=2.3+/–0.23mmol/L vs. 18 months=2.6+/–0.1mmol/L; p=0.003).
- A significant decrease in LDL– (baseline=4.4+/–0.8mmol/L vs. 18 months=3.6+/–0.8mmol/L, p<0.001] and total cholesterol (baseline=5.4+/–0.2mmol/L vs. 18 months=4.9+/–0.3mmol/L, p<0.001) were noted, as well as a significant improvement in HOMA–beta function (p=0.002).
- Majority of the improvements elicited were more prominent in women than men.
